Dec 6- U.S. regulators on Friday approved Gilead Sciences Inc's Sovaldi as a potentially easier cure for chronic infection with the liver-destroying hepatitis C virus. Most patients will be treated with the $1,000- a-day drug for 12 weeks, resulting in a total list price of $84,000, according to Gilead spokeswoman Cara Miller.» Read More
Here's a look at the latest contest stock action. Mergers and acquisitions played a strong part in the best performers (MedImmune, Baush & Lomb) as well as earnings figures (Angiodynamics). A couple of newer names showed up in the most active list (Ligand and Angiotech) while the widely held stocks stayed the same.
Good morning. We have a big change on the leaderboard. Kevin Boyd jumps from 4th place to take the lead after gaining over $419K with Gentex Corp. Serge Amelyan drops to #2 and continues to stay all in cash adding only $3,000 in Bonus Bucks to his portfolio. Kevin is #1 with a total portfolio value of $3,471,377.82 up $422,904.60 from Friday's total. He gained $419,904.60 on the sale of Gentex Corp which was up 13.77% Monday.
One of the world's most prominent peer-reviewed medical journals is weighing in on last week's U.S. Supreme Court decision on abortion.
Mylan Laboratories spacer said U.S. regulators approved its generic version of Sanofi-Aventis' sleeping pill, Ambien, in the 5 mg and 10 mg strengths.
In a previous blog post, I wrote about what happened at this year's American College of Cardiology conference in New Orleans when at least one doctor "leaked" the results of a major, highly anticipated study comparing drug-coated stents to old-fashioned heart drugs. The ACC had to move up the embargo time of the data by one day and reporters had to scramble to meet the hastened deadline.
Hey folks, guest blogger Jeff Mishlove has sent in this picks for today (Monday). Here's his post: By the close of the market on Friday, it was clear that the stocks I had recommended for purchase last Thursday were doing quite well. In particular, Intuitive Surgical , gained 8.71% in one day. Yet again, evidence continues to support my contention that the short squeeze
Time to put back Jonathan Tucker's photo in the blog post as the actor has pushed out poker champion Chris Moneymaker from the top spot in Trading With The Stars. Jonathan is now followed by fellow actor Stephen Collins in 2nd. Moneymaker lost on Cubist Pharma which fell 7.46% Thursday. It's a close race between the top 3, with only....
Good morning. Serge Amelyan continues to hold the top position on the overall leaderboard, while the upset occurs as Parker Robinson falls to third, displaced by Vitaliy Khizder who moves into 2nd. As we said Thursday, Serge is the first contestant to break the $3M mark with a total portfolio value of $3,275,721.77 up $39,498.72 from Wednesday's total on the sale of...
Here's our re-cap of today--with the leaderboard, most active and widely held stocks as well as our trivia questions. We'll start there. The video question is worth $2,000 Bonus Bucks: According to this morning’s report, China’s first quarter GDP was up how much? The selection of answers are: 5.7% or 8.5% or 10.2% or 11.1%.
Wow--we've gotten posts from all three guest bloggers today as this one from Timothy Sykes wraps it up. You certainly have some food for thought. Here's Timothy: Many contestants have been asking why I advocate such a seemingly risky strategy by focusing on chart plays with upcoming earnings. The answer, like my strategy, is rather simple.
Hey folks, time for the day's trivia questions. Here they are. The video question is worth $2,000 Bonus Bucks: According to this morning’s report, China’s first quarter GDP was up how much? The selection of answers are: 5.7% or 8.5% or 10.2% or 11.1%. The news trivia question is worth $1,000 Bonus Bucks: Merck reported that revenue climbed from the same quarter last year, boosted in part by sales of what cholesterol drug? The selection of answers are: Lipitor or Plavix or Zetia or Remicade.
It was a volatile day for the celebs. Champion poker player Chris Moneymaker holds onto the first spot despite his $90K loss on Syntel but actor Jonathan Tucker takes over the #2 spot. Meanwhile, Willie Garson falls into 4th, allowing Stephen Collins to gain 3rd place. Johnny Bench falls from 6th to 8th. One of the stocks for Chris M., CBST, is also a favorite of Parker Robinson in our non-celeb trading. Both are "banking" on it paying off.
Hey folks, here's guest blogger Jeff Mishlove's contest picks for today: Even though my seven stock choices for Tuesday were far from my best for this contest, the first stock on my list, Champion Enterprises did quite well, gaining 8.8% in a single day. And, another top choice, Interwoven, Inc. also gained 3.9% between Tuesday’s close and Wednesday’s close.
Hey folks--we have guest blogger Jeff Mishlove's contest picks for the day. Let's get right to his comments: Now that the Tuesday results are in, I see that my top recommendation for Monday had a significant price gain. That was Adtran, Inc., which rose 6.16%. This stock had a lot going for it: it was favored by hedge funds and professional investors; it was approaching its 52-week high; a significant amount of stock was controlled by short sellers..
We have more video from Friday night's contest program, "How To Win." Specifically, more stock picks from our guest analysts. One of them, Timothy Sykes, who is also a guest blogger, loves the charts as you'll hear him explain. He also explains, his picks could have an upside, as well as a down side. So it's buyer beware for sure (fyi--it's that way with all the picks!).
In case you missed it, here's a video portion of Friday night's "How To Win" program on the million dollar portfolio challenge. The show got right to the picks from the analysts, so I will do the same. Notice a bit of a theme--earnings reports coming out this week. Also, there are a couple of "bigger" names like Google and McDonald's to chose from.
John Goodman, president of the National Center for Policy analysis, told CNBC’s “Morning Call” that Health Savings Accounts are growing faster than IRAs at the “same point of their evolution.”
Ads for Pfizer Inc.'s Celebrex arthritis drug are set to splash across U.S. television screens on Monday after more than a two-year hiatus, with an unusual upfront focus on its risks rather than its benefits.
Plaintiff Frank Schwaller sued Merck after his wife, Patricia, took Vioxx for 20 months for shoulder pain before dying from a heart attack in August 2003.
Boston Scientific's stock slid on Monday while shares of Abbott Laboratories jumped after a study showed Abbott's drug-coated stent was better at treating clogged heart arteries.